Posted by Michael Wonder on 30 May 2023
Roche Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Vabysmo (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema
29 May 2023 - Roche Canada today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Vabysmo (faricimab injection), indicated for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular oedema, two of the leading causes of vision loss among Canadians.
Vabysmo was reviewed and positively recommended by Canada's Health Technology Assessment bodies, including CADTH in the fall of 2022, as well as Institut national d'excellence en santé et en services sociaux (INESSS) earlier in 2023, for the treatment of neovascular age-related macular degeneration and diabetic macular oedema.
